Advisory-led, capital-enabled investment banking, serving marquee legacy and new age companies
MUMBAI, India, Oct. 1, 2025 /PRNewswire/ — India’s deal-making landscape is undergoing a shift — with legacy businesses reinventing themselves and new-age firms raising growth capital at scale. At the centre of this momentum is InCred Capital’s Investment Banking (IB) platform, which has emerged as one of India’s highest-conversion franchises with over 200 completed transactions and more than US$8.5Bn closed across ECM, M&A, and private capital.
The edge is how mandates are run: one accountable team from start to finish, tight timelines, and the full weight of the firm behind every mandate — decision-makers in the room from first pitch to final signatures. The stance is advisory-first always, but when capital improves certainty or timing, the firm stands ready to commit its own balance sheet to anchor, bridge, or backstop.
InCred Capital has advised on marquee transactions, such as the ₹3,690 Cr rights issue for Indiabulls Housing Finance, the ₹2,825 Cr sale of Raymond’s consumer business to Godrej Consumer Products, and the ₹1,270 Cr preferential issue for UGRO. In the new-age ecosystem, it advised on the ₹1,000 Cr pre-IPO secondary stake sale of Swiggy, the ₹613 Cr capital raise for OYO, and the ₹490 Cr pre-IPO for Ethos Watches. The team also drove strategic moves like the ₹682 Cr M&A advisory for Raymond Group, the ₹470 Cr acquisition of OSAM Dairy by Dodla Dairy, and the ₹230 Cr capital raise for Livpure.
Most recently, InCred Capital acted as the exclusive financial advisor to Beroe, the global leader in procurement decision intelligence, on its ₹300 Cr (US$34 million) primary fundraise, cementing its role as a trusted partner to both high-growth scale-ups and global leaders in capital formation.
For more information, visit
https://www.incredcapital.com/
View original content:https://www.prnewswire.com/in/news-releases/incred-capital-cements-ib-standing-with-beroe-fundraise-302572174.html
•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…
Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…
June 05, 2026 19:30 ET | Source: Oban BioPharma, Inc. STAMFORD, Conn., June 05, 2026…
Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…
June 05, 2026 20:13 ET | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…
Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and…